Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations

Схожие документы

• Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
  по: Krawczyk, Paweł, et al.
  Опубликовано: (2012)
• The Incidence of EGFR-Activating Mutations in Bone Metastases of Lung Adenocarcinoma
  по: Krawczyk, Paweł, et al.
  Опубликовано: (2013)
• Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes
  по: Krawczyk, Paweł, et al.
  Опубликовано: (2017)
• Septin 9 promoter region methylation in free circulating DNA—potential role in noninvasive diagnosis of lung cancer: preliminary report
  по: Powrózek, Tomasz, et al.
  Опубликовано: (2014)
• Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations
  по: Krawczyk, Pawel, et al.
  Опубликовано: (2017)